Intervention to Promote Weight Loss in Latinas At-risk for Diabetes

• ClinicalTrials.gov Identifier: NCT02088034
• Recruitment Status: Completed
• First Posted: March 14, 2014
• Results First Posted: December 22, 2020
• Last Update Posted: December 22, 2020
• Sponsor: Temple University
• Information provided by (Responsible Party): Temple University

Study Description

Brief Summary:

The overarching goal of this project is to develop and test a behavioral intervention delivered by promotoras to help at-risk Latinas lose weight and prevent diabetes.

Condition or disease	Intervention/treatment	Phase
Diabetes	Behavioral: Promotora-led Intervention; Drug: Metformin Therapy; Other: Usual Care	Phase 4

Detailed Description:

The goal of the proposed research is to compare two evidence-based strategies for preventing type 2 diabetes - promotora-led lifestyle intervention and metformin - vs. usual care (UC) among Latinas in a "real world" setting. The aims of this study are to 1) develop a protocol-based, promotora-led lifestyle intervention (PLI) to promote weight loss in at-risk Latinas, and assess its feasibility; 2) compare changes in weight and cardiometabolic markers-hemoglobin A1C, fasting lipids, blood pressure-from baseline to 1 year between at-risk Latinas randomly assigned to the PLI group versus metformin and usual care (UC) groups; and 3) understand the social and cultural context surrounding weight-related behaviors among Latinas at-risk for diabetes. The investigators hypothesize that Latinas assigned to PLI and metformin will have greater weight loss (primary outcome) and greater improvements in cardiometabolic markers from baseline to 1 year than those randomized to UC

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 92 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Promotora-led Intervention to Promote Weight Loss in Latinas At-risk for Diabetes
• Study Start Date: September 2013
• Actual Primary Completion Date: February 2016
• Actual Study Completion Date: February 2016

Arms and Interventions

Arm	Intervention/treatment
Experimental: Promotora-led Intervention; The Promotora-led Intervention consists of a core curriculum or 12 group sessions of 90 minute duration over a 12-week period and will be followed by a maintenance phase of 10 biweekly and then monthly 90-minute sessions during months 4 through 12. One promotora will lead each session in Spanish, exploring such topics as being active, low-fat diets, portion control, self monitoring, problem solving and life-style changes.	Behavioral: Promotora-led Intervention; Behavioral life-style program lead by a team of trained community health workers (called promotoras) with 2 principal goals - encouraging participants to lose 7% of their total weight and complete 150 minutes of moderate physical activity per week.; Other Name: ILI
Active Comparator: Usual care; One physician visit at Puentes de Salud or Congreso Health Center to discuss healthy lifestyle behaviors that promote weight loss and diabetes prevention. During that visit, UC participants will also receive standard educational materials in Spanish from the NIDDK Weight-control Information Network covering the same topics. UC participants will receive another physician visit upon completion of 1-year follow-up to review laboratory assessments.	Other: Usual Care; Participants in this arm will attend one physician visit to discuss healthy lifestyle behaviors and will receive standard educational materials.; Other Name: Control
Active Comparator: Metformin Therapy; Participants randomized to the metformin arm of the study will receive this medication from months 1 through 12 after randomization. Subjects will receive 850 mg daily for 1 month and increase to 850 mg twice daily thereafter if no side effects are experienced.	Drug: Metformin Therapy; Participants in this group will receive metformin 850 mg bid for one year.; Other Name: Metformin

Outcome Measures

Primary Outcome Measures :

1. Body Weight [ Time Frame: 1 year ]
   Study tests difference in body weight (Weight in kg) between treatment conditions and usual care at 12 months.

Eligibility Criteria

• Ages Eligible for Study: 20 Years to 75 Years (Adult, Older Adult)
• Sexes Eligible for Study: Female
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Female gender
• Latino ethnicity
• Spanish fluency
• Age ≥20 years
• BMI ≥25 kg/m2
• And "increased risk of diabetes" (ADA Diabetes Risk Score ≥4 as determine by 7-item questionnaire and hemoglobin A1C ≥ 5.6%)

Exclusion Criteria:

• Hemoglobin A1C ≥ 6.5%
• Current or planned pregnancy during the study period
• Chronic conditions that could affect potential participants' ability to participate (osteoarthritis, heart disease, pulmonary disease requiring oxygen or daily bronchodilator use, and severe psychiatric disease)
• Medical comorbidities that could influence weight loss or weight gain (thyroid disease, cancer, and HIV)
• Medications that could affect weight or glucose metabolism (thiazide diuretics, β-blockers, and systemic glucocorticoids).

Contacts and Locations

Locations

United States, Pennsylvania

Temple University - Center for Obesity Research and Education

Philadelphia, Pennsylvania, United States, 19140

Sponsors and Collaborators

Temple University

Investigators

• Principal Investigator: Matthew J O'Brien, MD, MSc; Temple University

More Information

• Responsible Party: Temple University
• ClinicalTrials.gov Identifier: NCT02088034
• Other Study ID Numbers: 21273
• First Posted: March 14, 2014
• Results First Posted: December 22, 2020
• Last Update Posted: December 22, 2020
• Last Verified: November 2020

Additional relevant MeSH terms:

Diabetes Mellitus; Weight Loss; Glucose Metabolism Disorders; Metabolic Diseases; Endocrine System Diseases; Body Weight Changes; Body Weight; Metformin; Hypoglycemic Agents; Physiological Effects of Drugs